Trials / Completed
CompletedNCT00144547
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP
An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA012JP
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 241 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA012JP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRA(Tocilizumab) | 8mg/kg(i.v.)/4weeks |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2008-08-01
- Completion
- 2009-06-01
- First posted
- 2005-09-05
- Last updated
- 2013-08-09
Source: ClinicalTrials.gov record NCT00144547. Inclusion in this directory is not an endorsement.